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Abstract
Background: Peptidyl-prolyl cis/trans isomerase (Pin1), encoded by PIN1 gene with locus in chromosome 19p13, is
an enzyme that catalytically induces conformational changes in proteins after phosphorylation on serine or
threonine residues preceding proline (pSer/Thr-Pro motifs); in this way, it has an influence on protein interactions
and intracellular localizations of proteins. The aim of the study were: 1) an assessment of PIN1 gene expression
level in benign and malignant thyroid lesions; 2) the evaluation of possible correlations between gene expression
and histopathological variants of papillary thyroid carcinoma (PTC) or tumour size, classified according to TNM
classification of primary tumours (in case of PTC only); 3) the estimation of possible relationships between
expression of the gene in question and patients’ sex or age.
Methods: Seventy (70) tissue samples were analyzed: 32 cases of PTC, 7 cases of medullary thyroid carcinoma
(MTC), 7 cases of follicular adenoma (FA), and 24 cases of nodular goitre (NG). In real-time polymerase chain
reaction (real-time PCR), two-step RT-PCR (reverse transcriptase-polymerase chain reaction) in an ABI PRISM 7500
Sequence Detection System was employed. The PIN1 gene expression level was assessed, calculating the mean
relative quantification rate (RQ rate) increase for each sample.
Results: The level of PIN1 gene expression (compared to that in macroscopically unchanged thyroid tissue) was
higher in PTC group than those in FA, MTC and/or NG groups, but the statistical significance was noted for
difference between PTC and NG groups only. On the other hand, the differences of RQ rate value between
different PTC variants were statistically insignificant. No correlations were found between RQ values and tumour
size, as well as between RQ values and patients’ sex or age in PTC group.
Conclusions: The PIN1 gene expression may have - in future - an important meaning in the diagnostics of PTC
and in understanding its pathogenesis. However, our results - mostly due to the small number of cases - do not
yet allow considering PIN1 gene as a prognostic molecular PTC marker.
Background
The PIN1 gene encodes an essential peptidyl-prolyl cis/
trans isomerase (PPIase; EC 5.2.1.8) which has a pro-
found impact on key proteins involved in the regulation
of cell cycle [1]. The human PIN1 gene is mapped to
chromosome 19p13 [2]. Catalyzing conformational
changes in substrates after phosphorylation, Pin1 recog-
nizes phospho-serine or phospho-threonine bonds fol-
lowed by proline (pSer/Thr-Pro motifs) and plays a vital
role in protein folding or refolding [3]. Through
isomerization Pin1 can modulate the conformation of
protein substrates, changing their enzymatic activity
which leads to alteration in different cell function [1].
Pin1 enzyme activity is important for oncogenic and
cell-signalling pathways via conformational changes fol-
lowing phosphorylation of many molecules (e.g. Bcl-2,
p53, c-Jun, beta-catenin, cyclin D1 and RAF kinase)
[4-7]. The Pin1-regulated alteration in protein interac-
tions and stability have been shown to be associated
with cell transformation and progression of certain types
of human tumours (e.g., prostate, colon, lung, ovary and
breast cancers, and lymphoma) [8-10]. It has also been
reported that inhibition of Pin1 function in human
tumour cells, using Pin1 antisense RNA, induces mitotic
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Pin1 plays a critical role in cell restriction points - parti-
cularly in G1/S phase; Pin1 modulates some important
regulators of that cell cycle point, e.g. cyclin D1 and its
upstream transcriptional factors. The increased Pin1
expression correlates significantly with overexpression of
cyclin D1 mRNA and protein. Interestingly, Pin1 binds
phosphorylated c-Jun, influencing the increase of its
transcriptional activity towards cyclin D1 - by activating
c-Jun/AP-1 and beta-catenin/T-cell factor (TCF) and, in
this way it cooperates with Ras signalling pathway [4].
Pin1 is involved not only in the pathogenesis of
human cancer, but - presumably - also in the pathogen-
esis of asthma and Alzheimer’s disease [12].
Recently, in some reports - including the study on
thyroid tumours - strong correlation between Pin1 and
cyclin D1 immunoexpression and/or cyclin D1 mRNA
and PIN1 expression via interaction with Wnt signalling
pathway has been observed [13]. Moreover, it has been
suggested that Pin1 may promote cyclin D1 overexpres-
sion directly or through accumulation of beta-catenin in
thyroid cancer cells [13].
There are rather scarce reports which are focused on
evaluation of PIN1 mRNA expression in thyroid
tumours. Therefore, in order to recognize the Pin1 role
in the pathogenesis of thyroid gland, we have compared
the levels of PIN1 gene expression in benign and malig-
nant thyroid lesions. We have assessed PIN1 gene
expression in real-time polymerase chain reaction (real-
time PCR), two-step RT-PCR (reverse transcriptase-
polymerase chain reaction) and we have evaluated the
possible correlations between the gene expression and
the histopathological variant of examined PTCs (classic,
tall-cell, follicular), tumour size grouped according to
TNM classification of primary tumours (pT1, pT2, pT3,
pT4). We have also decided to estimate the possible
relationships between expression of the gene in question
and patients’ sex or age.
Materials and methods
The Ethical Committee of the Medical University of
Lodz approved the studies reported in the present
article.
Thyroid tissue samples
Tumour tissue samples (100-150 mg) were obtained
from 70 patients who had undergone surgery treatment
at the Centre of Oncology, the Maria Skłodowska-Curie
Institute in Gliwice, at the Holy Family Municipal Hos-
pital in Lodz and at the Department of General and
Colorectal Surgery, Medical University of Lodz, Poland
during the years 2002-2007. Total tumour tissue sam-
ples, immediately after resection, were collected into
lysis buffer (Buffer RLT, Qiagen Sciences, USA).
Among the studied samples 32 cases of primary papillary
thyroid carcinoma - PTC (26 females, 6 males; mean age
41.8 ± 15.7; mean ± SD) were used. Histopathological var-
iants of PTC were as follows: PTC classic variant (20 cases:
17 females, 3 males; mean age 36.5 ± 14.4), PTC follicular
variant (9 cases: 6 females, 3 males; mean age 49.9 ± 16.0),
PTC tall-cell variant (3 cases: 3 females; mean age 53.3 ±
5.1) (Table 1). Seven (7) cases of medullary thyroid carci-
noma - MTC (6 females, 1 male; mean age 56.0 ± 17.6)
and 7 cases of follicular adenoma - FA (6 females, 1 male;
mean age 49.4 ± 14.8) were also included in the study. The
control group consisted of 24 cases of nodular goitre - NG
(22 females, 2 males; mean age 48.9 ± 14.7) (Table 2).
The whole study cohort comprised 70 persons: 60
females and 10 males, the mean age was 46.4 ± 15.8
years (age ranged from 16 to 75 years). Histopathologi-
cal diagnoses for malignant thyroid lesions, according to
WHO Classification of Tumours [14], have been
obtained from pathomorphological reports and are pre-
sented in Table 1, together with TNM classification and
AJCC stage groupings [15].
In the study design, macroscopically unchanged thyr-
oid tissue served for the reference standard (calibrator).
Isolation of total RNA and reverse transcription (RT)
Total RNA was extracted from fresh tisssues, using
RNeasy Protect Midi Kit, (Qiagen, Hilden, Germany),
according to the manufacturer’s recommendations. RNA
concentration was spectrophotometrically assessed by
measuring absorbance at 260 and 280 nm (Ultraspec
2000 UV/Visible Spectrophotometer, Pharmacia Biotech,
Sweden).
Afterwards the reverse transcription (RT) was per-
formed in a Personal Thermocycler (Eppendorf, Ger-
many), using 1 μg of total RNA in the presence of 50
μM of oligo d(T)16 and Reverse Transcriptase Multi-
Scribe™ (50 U/μl) in a total volume of 30 μl, including
also: 10× TaqMan RT Buffer (containing 100 mM Tris-
HCL pH 8.3, 500 mM KCL), MgCl2 solution (25 mM),
dNTPs mixture (10 mM), RNAse Inhibitor (20 U/μl),
and nuclease-free water (TaqMan Reverse Transcriptase
Reagents, Applied Biosystems, Foster City, CA, USA).
The reactions were conducted for 10 minutes at 25°C,
followed by 30 minutes at 48°C, afterwards the samples
w e r eh e a t e df o r5m i nt o9 5 ° C ,a n dn e x tp l a c e da t4 ° C .
The cDNA concentration and purity were spectrophoto-
metrically assessed by measuring absorbance at 260 and
280 nm (Ultraspec 2000 UV/Visible Spectrophotometer,
Pharmacia Biotech, Sweden).
Quantitative analysis of the relative amount of PIN1
mRNA by real-time PCR
An established Relative Quantification Polymerase Chain
Reaction (RQ-PCR) assay for PIN1 mRNA expression
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System (Applied Biosystems), according to the manufac-
turer’s protocol. The PCR reactions for PIN1 gene were
run with 50 ng of cDNA in a total volume of 50 μl,
using TaqMan
® Universal PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) and the predesigned
and labelled primer/probe set (Assays-on-Demand™
Gene Expression assay mix, Hs01598309_ml, Applied
Biosystems). After initial incubation at 50°C for 2 min
to allow uracil-N-glycosylase (UNG) digestion, and at
95°C for 10 min to activate the AmpliTaq Gold
®DNA
polymerase, both of them were provided by the
Table 1 Sex, age, histopathological diagnosis of malignant thyroid tumours in the studied patients
Case
number
Sex Age Histopathological
diagnosis
TNM staging
system
American Joint Committee on Cancer (AJCC) grouping
system
1 F 23 PTC, classic variant pT1bNxM0 I
2 F 38 PTC, classic variant pT1N0M0 I
3 F 52 PTC, classic variant pT2N0M0 II
4 F 71 PTC, classic variant pT2N0Mx II
5 F 47 PTC, classic variant pT1aN0M0 I
6 F 24 PTC, classic variant pT1N0Mx I
7 F 33 PTC, classic variant pT2aNxMx II
8 F 28 PTC, classic variant pT1bNxMx I
9 F 40 PTC, classic variant pT4N0Mx IVA
10 F 17 PTC, classic variant pT2bN1aM0 III
11 M 47 PTC, classic variant pT2aN1aM0 III
12 M 31 PTC, classic variant pT2aN0M0 II
13 F 16 PTC, classic variant pT2aN0M0 II
14 F 61 PTC, classic variant pT2aN0M0 II
15 F 48 PTC, classic variant pT4N1aM0 IVA
16 M 30 PTC, classic variant pT4N1bM0 IV
17 F 31 PTC, classic variant pT1NxMx I
18 F 40 PTC, classic variant pT1aNxMx I
19 F 28 PTC, classic variant pT1aNxMx I
20 F 25 PTC, classic variant pT1aN1aMx I
21 F 49 PTC, tall-cell variant pT2bN0M0 II
22 F 52 PTC, tall-cell variant pT4N0M0 IVA
23 F 59 PTC, tall-cell variant pT4bN1Mx IV
24 F 36 PTC, follicular variant pT2aNxMx II
25 M 28 PTC, follicular variant pT2N1aMx II
26 M 52 PTC, follicular variant pT3NxMx III
27 F 62 PTC, follicular variant pT1aNxMx I
28 F 26 PTC, follicular variant pT4N1aM0 IVA
29 F 56 PTC, follicular variant pT3aN0M0 III
30 F 68 PTC, follicular variant pT2bN1aM0 II
31 M 66 PTC, follicular variant pT4aN0M0 IVA
32 F 55 PTC, follicular variant pT2aN0M0 II
33 M 74 MTC pT4N0M0 IVA
34 F 32 MTC pT1NxMx I
35 F 32 MTC pT1NxMx I
36 F 59 MTC pT3N1bM0 III
37 F 56 MTC pT3N0M0 III
38 F 71 MTC pT4N1aM0 IVA
39 F 68 MTC pT3aN0M0 III
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through 40 biphasic cycles of 95°C for 15 sec and 60°C
for 1 min (Table 3).
Macroscopically unchanged thyroid tissue was used as
a calibrator (standard sample). Amplification reactions
were done in triplicate for each sample (cDNA from the
same PCR reaction but in separate wells). Controls with
no template cDNA were used with each assay (negative
control).
The expression levels of b-actin gene (ACTB)w e r e
measured, as endogenous control (reference gene), using
the appropriate Assays-on-Demand™ Gene Expression
product (Hs99999903_ml, Applied Biosystems Foster
City, CA, USA).
Both gene expressions were measured for each thyroid
lesion sample in the same PCR reaction but in separate
wells.
Assays-on-Demand™ Gene Expression product consists
of 20 × mix of unlabelled PCR primers (18 μM for each)
and TaqMan
® MGB probes (5 μM) with FAM™ (6-car-
boxy-fluorescein) at the 5’ end as the reporter dye, and
a non-fluorescent quencher (TAMRA, 6-carboxy-tetra-
methylrhodamine) at the 3’ end. The two-minute, 50°C
step was required for optimal AmpErase
® UNG activity
when TaqMan
® Universal PCR Master Mix (P/N
4304437) was used.
The fluorescence signal was measured in real-time
PCR in the extension phase of the PCR reaction, and
the measurement, proportional to the quantity of sample
cDNA in the reaction, was plotted as an amplification
curve against cycle number. A threshold value of fluor-
escence in the exponential part of the amplification
curve was selected, and - for each sample - the number
of cycles was measured, which was needed by the signal
to reach the threshold (threshold cycle, CT). The larger
were the quantities of the starting material, the lower
were CT values.
Data analysis
Data analysis of relative gene expression was performed
with the Taq-Man SDS analysis software on an ABI
PRISM 7500 Sequence Detection System (Applied Bio-
systems), and the results were exported to Excel sheets
for further processing.
Fluorescence emission data were determined as CT
values for each reaction and, for each sample, triplicate
CT values were averaged. The average CT value for b-
actin was subtracted from the average PIN1 CT value to
yield the ΔCT value (ΔCT =C T target - CT reference).
Normalization to the reference gene (b-actin) has been
necessary to account for the variabilities in sample
quantity and quality, and for the variabilities in PCR
efficiency among samples. The assay, described in this
report, involves the determination of a ΔΔCT value.
This is calculated by: ΔΔCT = ΔCT test sample - ΔCT
calibrator sample. The higher is the ΔΔCT value, the
lower is the expression of PIN1 in the specimen. Fold-
Table 2 Sex, age, histopathological diagnosis of benign
thyroid lesions in the studied patients
Case number Sex Age Histopathological diagnosis
1 F 49 FA
2 F 52 FA
3 M 75 FA
4 F 29 FA
5 F 41 FA
6 F 41 FA
7 F 59 FA
8 F 40 NG
9 F 42 NG
10 F 30 NG
11 F 48 NG
12 F 42 NG
13 F 64 NG
14 F 69 NG
15 F 72 NG
16 F 50 NG
17 F 51 NG
18 F 63 NG
19 F 49 NG
20 F 49 NG
21 F 38 NG
22 M 52 NG
23 F 31 NG
24 F 29 NG
25 M 75 NG
26 F 28 NG
27 F 30 NG
28 F 72 NG
29 F 50 NG
30 F 40 NG
31 F 59 NG
Table 3 Real-time PCR conditions for PIN1 gene
amplification
Times and temperatures
Initial setup Each of 40 cycles
Denaturation Annealing/
Elongation
HOLD HOLD CYCLE
UNG activation 2 min,
50°C
10 min,
95°C
15 s, 95°C 1 min, 60°C
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calculated using the following equation: relative fold
increase = 2
-ΔΔCT. In order to evaluate the analytical
sensitivity, specificity, and accuracy of the assay, serial
dilutions were performed.
Statistical analysis
The data were statistically analyzed, using Newman-
Keuls’ multiple comparison test followed by Kruskal-
Wallis’ test, in order to compare the level of expression
values (RQ) among the four studied independent groups
(PTC, MTC, FA, NG). Basic measures of location (i.e.
mean, median), measures of dispersion (SD, SEM), and
minimum and maximum values were calculated to pro-
vide detailed descriptions of gene expressions in selected
groups. Additionally, box-and-whiskers plots were intro-
d u c e dt od i s p l a yt h ed i f f e r e n c ei ng e n ee x p r e s s i o n s
levels in different samples.
The Kruskal-Wallis’ test was used to compare the
level of expression values (RQ) among three variants of
PTC (PTC v. classic, PTC v. tall-cell, PTC v. follicular).
The Spearman’s rank correlation coefficient and U
Mann-Whitney’s test were performed in order to corre-
late the level of expression of PIN1 gene (RQ values)
with examined parameters (age, sex, tumour size, classi-
fied according to TNM definition of primary tumours -
pT1, pT2, pT3, pT4).
The accepted level of statistical significance was at p <
0.05. The results are presented as means ± SEM and
means ± SD values.
Statistica for Windows 7.0 program was applied for
calculations.
Results
The specimens were amplified in the ABI PRISM 7500
Sequence Detection System in reaction, containing pri-
mers and probes for PIN1 gene and a control gene, b-
actin. The Sequence Detection System software, pro-
vided with the instrument, analyses the fluorescence
data, generated during the reaction, and calculates the
cycle number at which fluorescence crosses the thresh-
old value (CT). Triplicate amplifications of the sample
produced nearly identical, overlapping curves, from
which CT values were calculated.
In our experiment low CT values for PIN1 gene in all
malignant thyroid tissues (PTC - 32 and MTC - 7 speci-
mens) were observed.
The assay, described in this paper, was based on the
determination of a ΔΔCT value (ΔΔCT method) for each
sample (the greater was the ΔΔCT value, the lower was
the expression of PIN1 gene) and on calculating the dif-
ference in PIN1 expression level between tumour sample
and calibrator (RQ value). The results for calculated RQ
in the studied groups (PTC, MTC, FA, NG) are
presented in Table 4. The RQ value for PTC, classic var-
iant, ranged from 0.441 to 52.279 (the mean RQ was
8.43); for PTC, follicular variant, ranged from 0.804 to
9.124 (the mean RQ was 3.03) and for PTC, tall-cell var-
iant, ranged from 0.363 to 12.616 (the mean RQ was
6.42).
Kruskal-Wallis’ test, applied for RQ comparison
between the four studied groups (PTC, MTC, FA, NG),
showed statistically significant differences (p = 0.0233)
among them (Figure 1). The results of Newman-Keuls’
multiple comparison test revealed statistically significant
differences in RQ values only between the PTC group
(higher RQ values) and the control group - NG (p =
0.031977). In cases of other groups, the differences in
RQ values were not significant (p > 0.05) (Table 5).
Similarly, the results of Kruskal-Wallis’ test did not
show any significant differences among the particular
variants of PTC (PTC v. classic, PTC v. tall-cell, PTC v.
follicular) (p = 0.9501) (Figure 2). Additionally, in the
whole studied group of PTCs, no correlations were
Table 4 The expression level (RQ) of PIN1 gene,
calculated by the ΔΔCT method in the studied groups
Group No. of cases Mean RQ Range of RQ values
PTC 32 6.72 0.363-52.279
MTC 7 5.55 0.917-19.408
FA 7 2.79 0.511-8.207
NG 24 2.15 0.322-13.153
Figure 1 Box-and-whisker plots, representing the expression of
PIN1 gene in the studied groups (PTC, MTC, FA, NG). Results are
calculated as RQ values. Whiskers represent means ± SD (standard
deviation) for particular groups. Boxes represent means ± SEM
(standard error of mean). The data were statistically analyzed, using
Newman-Keuls’ multiple comparison test, followed by Kruskal-Wallis’
test, in order to compare the level of expression values (RQ) among
the four studied independent groups, p < 0.05; * - p < 0.031977
(Neuman-Keuls’ test).
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age or tumour size (p > 0.05). The results of Mann-
Whitney’s U test confirmed no significant differences in
RQ values between the PTC group and MTC group (p
= 0.6873) (Figure 3).
Discussion
The molecular pathogenesis of thyroid cancer is very
complex and still unclear. Recent molecular studies on
thyroid carcinogenesis have proved that many specific
genetic alterations in protooncogenes are associated
with development of thyroid cancer [16,17]. The muta-
tional activation of MAPK/ERK signalling pathway is
crucial to understand the carcinogenesis in the thyroid.
The mutations of genes coding effectors of MAPK/ERK
pathway (RET, RAS, NTRK1, BRAF) which rarely over-
lap, may be identified in more than 70% of PTC cases
[18-20]. Additionally, the chromosomal rearrangements
(RET/PTC or Trk) appear to be of crucial importance in
activation of MAPK/ERK pathway [21,22].
Despite the fact that constitutive activation of the
above mentioned pathway is a very important for the
development of thyroid cancer, many other molecular
regulatory mechanisms, involved in thyroid cancer
transformation, are recognized.
I no u rs t u d y ,w eh a v ee x a m i n e dw h e t h e rt h ePIN1
gene participates in thyroid carcinogenesis.
The phosphorylation of proteins on serine or threo-
nine residues preceding proline (pSer/Thr-Pro motifs),
catalized by the peptidyl-prolyl cis/trans isomerase Pin1,
has been confirmed as a major cell transformation
mechanism activating different oncogenic pathways in
many types of human tumours (including thyroid can-
cer) [9,13,23,24]. In immunohistochemical studies of
thyroid tumours, as well as of other types of cancers (e.
g., oral squamous carcinoma), high Pin1 expression pro-
motes cyclin D1 overexpression, directly or through
accumulation of beta-catenin [13,25]. It has been
reported that PIN1 expression is regulated by the tran-
scription factor E2F and Neu/Ras signalling. The
enhanced expression and stability of cyclin D1 by tran-
scriptional activation and/or posttranslational stabiliza-
tion by PIN1 gene or Pin1 protein may lead to cell
proliferation and transformation. Therefore, PIN1 might
be a crucial factor in modulating upregulation of cyclin
D1 level by Neu/Ras oncogenic signalling [7,26].
Bearing in mind all these facts, in our present study,
we have assessed PIN1 gene expression level in benign
and malignant thyroid lesions. In our earlier study, we
demonstrated that cyclin D1 gene expression levels were
higher in malignant thyroid tumours (PTC, MTC),
Table 5 Statistical analysis of results - comparison of RQ
value among the four studied groups (PTC, MTC, FA, NG).
Newman-Keuls’ test, p - level of significance
PTC MTC FA NG
PTC 1.000000 1.000000 0.031977
MTC 1.000000 1.000000 0.154248
FA 1.000000 1.000000 1.000000
NG 0.031977 0.154248 1.000000
Figure 2 Box-and-whisker plots, representing the difference in
the expression of PIN1 gene in the variants of PTC (PTC v.
classic, PTC v. tall-cell, PTC v. follicular). Results are calculated as
RQ values; no significant differences among studied groups are
shown. Whiskers represent means ± SD (standard deviation) for
particular groups. Boxes represent means ± SEM (standard error of
mean). The results were statistically analyzed using Kruskal-Wallis’
test, p = 0.9501.
Figure 3 Box-and-whisker plots, representing the difference in
the expression of PIN1 gene between the PTC group and the
MTC group. Results are calculated as RQ values; no significant
differences between studied groups are demonstrated. Whiskers
represent means ± SD (standard deviation) for particular groups.
Boxes represent means ± SEM (standard error of mean). The results
were statistically analyzed using Mann-Whitney’s U test, p = 0.6873.
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present results have revealed statistically significant dif-
ferences in expression of PIN1 mRNA between PTC
group and benign thyroid lesions (FA, NG) (higher RQ
value in PTC). It should be stressed that our data are in
accordance with observations of other authors [13].
Nakashima et al. [13] have observed overexpression of
cyclin D1 mRNA in PTC (thyroid tumours from a
radiocontaminated area), taking course with high
expression of PIN1 gene. In the quoted paper, correla-
tion between high Pin1 protein level and cyclin D1
immunoexpression level in PTC has also been con-
firmed [13]. It is important that Pin1 can promote cyclin
D1 overexpression directly or through beta-catenin sta-
bilization [6,13]. Our present results, which have focused
on PIN1 mRNA expression, as well as our earlier data,
concerning cyclin D1 mRNA overexpression in thyroid
malignancy, may suggest that one of the major regula-
tory mechanisms in cell transformation in thyroid carci-
nogenesis is PIN1 gene activity [27]. It is tempting to
speculate that PIN1 gene positively regulates cyclin D1
gene function not only through posttranslational stabili-
zation but also by an effect on transcriptional level.
In our present study, we have applied real-time relative
quantification PCR assay for PIN1 mRNA expression
and, employing this extremely sensitive and precise
method, we have confirmed overexpression of PIN1 gene
i nP T C .T h e s er e s u l t sm a ys u g g e s tad i a g n o s t i cu t i l i t yo f
PIN1 mRNA expression - as a malignant lesion marker -
for thyroid PTC. However, the results should be con-
firmed in larger number of PTC cases. The utility of
PIN1 g e n em a yb e-i nf u t u r e-v e r yc r u c i a lf o rd i a g n o s -
tics and treatment of thyroid cancer (especially of PTC),
based on the facts that overexpression of Pin1 has been
found to be an excellent prognostic marker in some
other human cancers (e.g., prostate, breast, colorectal
cancers) [8,10,23]. In these immunohistochemical stu-
dies, strong relationship between Pin1 protein level and
clinical outcome has been observed [8,10,23]. Unfortu-
nately, it is difficult to discuss the relationship between
PIN1 mRNA and prognosis in PTC, because - according
to our knowledge - there were no reported studies, focus-
ing on the evaluation of PIN1 gene expression in associa-
tion with pathological features and clinical outcome of
PTC, so far. Our present data have not documented any
significant differences in the expression level of PIN1
mRNA among the particular variants of PTC (classic vs.
tall-cell, vs. follicular variants). Moreover, no correlations
were found between PIN1 expression level and patients’
sex, age or tumour size in PTC group.
In summary, PIN1 gene expression may have - in
future - certain significance in PTC diagnostics and in
understanding its pathogenesis. However, our results -
due to the small number of cases - do not yet allow
considering PIN1 gene as a prognostic molecular PTC
marker.
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